Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
Vindesine at a dose of 3 mg/m2 i.v. once a week failed to produce responses in 24 adequately treated patients with measurable advanced renal carcinoma. Leukopenia and peripheral neurotoxicity were the most often observed side-effects. On the basis of the negative result, the application of vindesine in this disease is not recommended.
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014751:Vindesine
D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D014751:Vindesine